参麦注射液辅助紫杉醇联合卡铂化疗治疗非小细胞肺癌的疗效观察

Effect of Shenmai injection combined with paclitaxel and carboplatin in the treatment of non-small cell lung cancer

目的分析参麦注射液辅助紫杉醇联合卡铂化疗方案治疗非小细胞肺癌的效果。方法以我院2016年1月-2021年3月收治的52例肺癌患者为研究对象,以单双号法随机分为单纯化疗组26例与辅助治疗组26例。单纯化疗组行紫杉醇联合卡铂化疗方案,辅助治疗组在单纯化疗组基础上予以参麦注射液辅助治疗,对比2组临床效果。结果疾病缓解率,辅助治疗组略高于单纯化疗组,但差异无统计学意义(P>0.05)。生活质量评分,化疗前差异无统计学意义(P>0.05);化疗后,辅助治疗组评分高于单纯化疗组,差异具有统计学意义(P<0.05)。不良反应发生率,化疗后辅助治疗组低于单纯化疗组(P<0.05)。化疗前,2组T细胞亚群及NK细胞对比无明显差异(P>0.05);化疗后,辅助治疗组的CD_(3)^(+)、CD_(4)^(+)、NK细胞水平较同组治疗前有明显提升(P<0.05)、CD_(8)^(+)较同组化疗前无明显差异(P>0.05),而单纯化疗组治疗后CD_(3)^(+)、CD_(4)^(+)较化疗前有所降低,CD8+较化疗前有所提高,但无统计学差异(P>0.05);而2组化疗后对比,辅助治疗组CD_(3)^(+)、CD_(4)^(+)、NK细胞水平均高于单纯化疗组,CD_(8)^(+)低于单纯化疗组,差异显著(P<0.05)。结论参麦注射液辅助紫杉醇联合卡铂化疗方案治疗非小细胞肺癌,具有明显增效减毒作用,利于提高患者免疫功能并改善生活质量。

Objective To analyze the effect of Shenmai injection combined with paclitaxel and carboplatin chemotherapy in the treatment of non-small cell lung cancer.Methods 52 patients with lung cancer in our hospital from January 2016 to March 2021 were randomly divided into simple chemotherapy group(26 cases)and adjuvant treatment group(26 cases).The simple chemotherapy group was treated with paclitaxel combined with carboplatin chemotherapy,and the adjuvant treatment group was treated with Shenmai Injection on the basis of simple chemotherapy group.The clinical effects of the two groups were compared.Results The remission rate of the adjuvant treatment group was slightly higher than that of the chemotherapy group,and the difference was not statistically significant(P>0.05);Quality of Life score,before chemotherapy,statistically insignificant(P>0.05),adjuvant therapy group scores after simple chemotherapy group,statistically significant(P<0.05);The incidence of adverse reactions in the adjuvant treatment group was lower than that in the chemotherapy group(P<0.05);Before chemotherapy,there was no significant difference in T cell subsets and NK cells between the two groups(P>0.05).After chemotherapy,the levels of CD_(3)^(+),CD_(4)^(+),NK cells in the adjuvant treatment group were significantly higher than those in the same group before treatment(P<0.05),and there was no significant difference in CD_(8)^(+)compared with those in the same group before chemotherapy(P>0.05).However,the levels of CD_(3)^(+),CD_(4)^(+)in the simple chemotherapy group were lower than those before chemotherapy,and CD8+was higher than those before chemotherapy,But there was no statistical difference(P>0.05).After chemotherapy,the levels of CD_(3)^(+),CD_(4)^(+)and NK cells in the adjuvant treatment group were higher than those in the chemotherapy group,and CD_(8)^(+)was lower than that in the chemotherapy group,with significant difference(P<0.05).Conclusion Shenmai injection combined with paclitaxel and carboplatin chemotherapy in the treatment of non-small cell lung cancer has obvious synergistic and attenuation effect,which is conducive to improving the immune function and quality of life of patients.